(NEO) NeoGenomics - Ratings and Ratios

NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing services, operating a network of laboratories across the United States and the United Kingdom. The company's services are segmented into two main categories: Clinical Services and Advanced Diagnostics. Through these segments, NeoGenomics offers a comprehensive range of testing services to a diverse client base, including hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. This broad range of clients enables the company to provide testing services that cater to various needs, from diagnostic testing to clinical trials support.

The company's testing services portfolio is extensive, encompassing cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and digital imaging. Cytogenetics testing, for instance, involves the study of normal and abnormal chromosomes and their relationship to diseases, providing valuable insights into genetic abnormalities. Fluorescence in-situ hybridization testing, on the other hand, focuses on detecting and locating specific DNA sequences and genes on chromosomes, which is crucial for understanding genetic mutations. Additionally, the company offers flow cytometry testing to measure the characteristics of cell populations, as well as immunohistochemistry and digital imaging testing to localize cellular proteins in tissue sections. These services allow clients to visualize scanned slides and perform quantitative analysis for various stains, facilitating more accurate diagnoses and treatment plans.

NeoGenomics also provides molecular testing services, which involve the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level. This type of testing is critical for understanding the genetic basis of diseases and developing targeted therapies. Furthermore, the company offers morphologic analysis, which involves the examination of cells under a microscope by a pathologist for diagnostic purposes. To support its pharmaceutical clients' oncology programs, NeoGenomics provides testing services that cover discovery and commercialization, enabling these clients to bring new cancer treatments to market more efficiently. With its strong foundation in genetic testing and commitment to innovation, NeoGenomics, Inc. has established itself as a trusted partner in the field of cancer diagnostics and research.

Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics, Inc. has evolved into a prominent player in the life sciences industry. The company's common stock is listed on the NASDAQ exchange under the ticker symbol NEO, and its ISIN is US64049M2098. As a member of the Life Sciences Tools & Services sub-industry, NeoGenomics, Inc. is well-positioned to continue providing cutting-edge genetic testing services that support the development of innovative cancer treatments and improve patient outcomes. For more information about the company, its services, and its mission, visitors can access its website at https://www.neogenomics.com.